Additionally, the strategy of gene silencing that targets CBL-b has been shown to enhance the immune function of T lymphocytes, increase their cytotoxicity against RM-1 prostate cancer cells, and significantly inhibit tumor growth in immune mice, suggesting its potential as a therapeutic approach. Here, CBLB is linked to prostate cancer.